GLP-1 receptor agonists in metabolic research

The incretin axis

Glucagon-like peptide-1 is an incretin hormone released from intestinal L-cells in response to nutrient intake. It acts at the GLP-1 receptor, a class B G-protein-coupled receptor, coupling primarily to Gs and raising intracellular cAMP. Native GLP-1 is cleaved by dipeptidyl peptidase-4 within minutes, which is why the unmodified hormone has almost no utility as a research tool for sustained exposure work.

Every therapeutic-class analog in circulation is a solution to that clearance problem. Substitution at position 8 blocks DPP-4 cleavage; fatty-acid acylation confers reversible albumin binding that extends circulating half-life from minutes to days. The receptor pharmacology is largely conserved — what changes is exposure.

Single, dual and triple agonism

Semaglutide is a mono-agonist selective for GLP-1R, carrying an alpha-aminoisobutyric acid substitution at position 8 and a C18 diacid linked through a spacer at position 26. Tirzepatide is a dual GIP/GLP-1 receptor agonist built on a GIP backbone, with reported bias toward GIP receptor activity relative to GLP-1. Retatrutide adds glucagon receptor agonism, making it a triple GIP/GLP-1/GCGR agonist.

The pharmacological interest in adding receptors is not additive potency but divergent downstream biology: GIP receptor activation modulates adipocyte behaviour and appears to attenuate GLP-1-associated emetic signalling in preclinical models, while glucagon receptor agonism contributes an energy-expenditure component absent from the incretin arms.

Amylin analogs and combination work

Cagrilintide is a long-acting amylin analog acting at calcitonin and amylin receptor complexes — a different axis entirely from the incretins, mediating satiety signalling through the area postrema. CagriSema combines cagrilintide with semaglutide, and in preclinical literature the combination is studied specifically for non-overlapping mechanism rather than dose escalation of either component.

In comparative in vitro work this matters methodologically. Receptor-selective readouts must be chosen to isolate the arm being interrogated, because a cAMP assay in a cell line expressing multiple receptors of the class cannot attribute signal to a single receptor.

Handling considerations for this class

Acylated analogs are surface-active and adsorb readily to glass and plastic at low concentrations, which produces apparent potency loss that is a handling artefact rather than degradation. Low-bind labware and a carrier protein in the diluent mitigate this in dilute work.

These compounds are also aggregation-prone at high concentration under agitation. Reconstitute slowly, avoid vortexing, and inspect for opalescence before use — a faint haze in a solution that was clear yesterday is fibrillation, not a lighting artefact.

Why incretin analogs are engineered the way they are

Native GLP-1 is cleaved within about two minutes by dipeptidyl peptidase-4, which removes the first two residues and abolishes receptor activity. Essentially every design decision in the analog class follows from that fact. Substitution at position 8 blocks the DPP-4 cleavage site; fatty-acid acylation with a linker provides reversible albumin binding, which both shields the molecule from renal filtration and creates a circulating depot.

The consequence in research terms is that exposure and receptor activity are separate variables that must be interpreted separately. In a receptor assay with no clearance, an acylated analog may appear no more active than the native peptide; in a preclinical model, the same modification changes the experiment entirely. Comparisons that do not state which system produced the numbers are of limited use.

Multi-receptor analogs extend the logic. Adding GIP receptor activity, or GIP and glucagon receptor activity, produces compounds characterised by the ratio of potencies across targets rather than by a single value. Those ratios are species-dependent, because the receptors used in the assay may be human, murine or a mix.

Reading the class literature critically

Published potencies for this class span wide ranges, and most of the spread is methodological. cAMP accumulation in a cell line overexpressing the receptor gives a very different number from the same measurement in a line with physiological expression, because receptor reserve shifts the functional EC50 away from binding affinity.

Beta-arrestin recruitment is the second axis. Analogs differ in how strongly they drive receptor internalisation relative to G-protein signalling, and that difference only becomes visible over longer incubations. Two compounds matched on acute cAMP potency can diverge markedly on sustained signalling.

For laboratory documentation purposes the practical implications are mundane but important: these are large, modified sequences whose analytical characterisation should include mass confirmation of the acyl modification, not only purity, because incomplete or misplaced acylation is a plausible synthesis-related impurity that a purity percentage will not identify.